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ABSTRACT 
 
LINDA CHAN: MicroRNAs: New Insights Into the Pathogenesis of  
Endodontic Periapical Disease 
(Under the direction of Asma Khan, Salvador Nares, Ricardo Padilla and Eric Rivera) 
 
Apical periodontitis is an inflammatory disease of the periradicular tissues caused by the 
host’s immune response to infection of the root canal system. MicroRNAs (miRNA) have 
been shown to play an important role in the regulation of inflammation and the immune 
response; however, their role in the pathogenesis of endodontic periapical disease has not 
been explored. The purpose of this study was to examine the differential expression of 
miRNAs in diseased periapical tissues as compared to healthy periodontal ligament and pulp 
tissues. miRNA profiles were assessed using microarray technology and expression levels of 
selected miRNAs linked to inflammation and the immune response were confirmed by 
quantitative RT-PCR. Of the 381 miRNAs identified using microarray, 24 miRNAs were 
down-regulated in diseased periapical tissues compared to controls (n=13) (P<0.003).  
Down-regulation of 7 of 9 selected miRNAs was confirmed by qRT-PCR in a separate set of 
diseased and healthy tissues (n=19) (P<0.05). Target genes of these miRNAs include key 
mediators in the immune and inflammatory response such as of IL-6, MMP-9 and TGF-β. 
These findings offer new insight into the pathogenesis of endodontic disease and have the 
potential to impact the development of new methods for prevention, diagnosis, and treatment 
of apical periodontitis.  
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CHAPTER 1: INTRODUCTION 
1.1 Pathogenesis of endodontic disease 
Endodontic disease is characterized by inflammation of the pulp and the periapical tissues. In 
endodontic disease, the tooth pulp first becomes infected with oral microflora either via 
caries, fractures, cracks, coronal microleakage or operative dental procedures, which then 
leads to necrosis of the pulp tissues.  This involves a mixed, predominantly gram-negative, 
anaerobic bacterial flora that elicits an initial immune response in the dental pulp (1-3).  
These microorganisms accumulate and become organized in biofilms where the cells are 
embedded in a polysaccharide complex that the host defenses are incapable of eliminating 
(4).  The microbial invaders progress towards the apex and eventually their byproducts such 
as lipopolysaccharides (LPS) are able to move through the apical foramen, reaching the 
periapex (5).  Their egress from the apical foramen stimulates a secondary immune response 
in the periapical region that involves an initial innate immune response followed by the 
activation of the adaptive immune response.  This process can be viewed as the body’s 
defense response to the infected root canal space in its attempt to localize the infection and 
prevent its spreading and systemization (6, 7).  First, the innate immune response is activated, 
which involves phagocytic leukocyte migration and proinflammatory cytokine production.  
Next the adaptive immune response becomes activated, which involves T and B cells.  Host 
derived factors such as cytokines, arachidonic acid metabolites and neuropeptides are 
expressed to modulate this inflammatory process. 
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1.2 Pathogenesis of apical periodontitis 
The inflammatory disease of the periradicular tissues, apical periodontitis, has great 
structural variation, especially in chronic lesions (8).   However, initial tissue changes are 
characterized by hyperemia, vascular congestion, edema of the periodontal ligament and 
extravasation of neutrophils (9).  High concentrations of neutrophils and some macrophages 
are found in the acute phase of apical periodontitis while lymphocytes, macrophages and 
plasma cells rise in number during the chronic phase of the disease process (10, 11).  
Neutrophils are drawn to the area of tissue injury by chemotaxis induced by LPS and 
complement factor C5a.  Neutrophils then release prostaglandins and leukotrienes such as 
leukotriene B4 (LTB4) which attracts more neutrophils as well as macrophages to the 
periapex.  Prostaglandins are derived from arachidonic acid when it is metabolized through 
the cyclooxygenase pathway.  The prostaglandins, prostaglandin E2 (PGE2) and 
prostaglandin I2 (PGI2) activate osteoclasts resulting in bone resorption (12).  Neutrophils, 
which are the predominant cell type in the acute phase of inflammation, are an important 
source of PGE2.  Leukotrienes are formed from the oxidization of arachidonic acid via the 
lipoxygenase pathway.  LTB4 is a strong chemotactic agent for neutrophils and facilitates the 
adhesion of PMNs to endothelial cell walls.  PMNs contain cytoplasmic granules with many 
enzymes capable of degrading cell structures and extracellular matrices, including several 
matrix metalloproteinases.   Although the primary role of PMNs is to destroy 
microorganisms, host tissues inevitably become damaged in the process as neutrophils die in 
large numbers at the site of inflammation, releasing their degradative enzymes, which do not 
discriminate between microbes and host tissues. 
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Macrophages enter the periapex later in the acute stage of the inflammatory response 
and produce several key mediators such as proinflammatory cytokines, IL-1, IL-6, and TNF, 
as well as chemotactic cytokine, IL-8.  These cytokines increase the local vascular response, 
bone resorption and degradation of the extracellular matrices.  They also work with IL-6 to 
up-regulate hematopoietic colony stimulating factor production, which mobilizes neutrophils 
and promacrophages from the bone marrow.  Antigen-antibody complexes are formed in the 
later stages of the acute response as well (13).  Proinflammatory and chemotactic cytokines 
involved in the pathogenesis of apical periodontitis include IL-1, IL-6, IL-8, and TNF (14).  
IL-1β is the main form expressed in human periapical lesions and their exudates (15, 16).  
This cytokine enhances the adhesion of leukocytes to endothelial walls, stimulates 
lymphocytes, potentiates neutrophils, activates prostaglandin and proteolytic enzyme 
synthesis, increases bone resorption and inhibits bone formation (12, 17).  IL-6 down-
regulates the production of IL-1.  IL-8 is a chemotactic cytokine produced by monocytes and 
fibroblasts under the influence of Il-1β and TNF-α and is involved in regulating PMN and 
monocyte infiltration (18).  TNF-α from macrophages and TNF-β from T-lymphocytes have 
many local effects similar to IL-1 (12).   
In the chronic phase of apical periodontitis, the cellular composition shifts from a 
neutrophil dominated lesion to a macrophage, lymphocyte and plasma cell dominated lesion 
enclosed in a collagenous connective tissue periphery.  Macrophage derived proinflammatory 
cytokines stimulate lymphocytes differentiation.   T-cells outnumber B-cells and there are 
more CD4+ cells than CD8+ (11, 19-21).  T-cells produce many cytokines that down-regulate 
the production of proinflammatory cytokines, thus suppressing osteoclastic activity, while 
also up-regulating the production of growth factors such as TGF-β.  TGF-β is involved in the 
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activation of macrophages, proliferation of fibroblasts, synthesis of connective tissue, 
angiogenesis and down-regulation of many T-lymphocyte functions, thus helping to counter 
some of the damaging effects of the inflammatory response (22, 23).   
A periapical lesion is formed as a result of this dynamic interaction between the host 
defense response and the bacteria contained in the root canal system.  This inflammatory 
disease of the periradicular tissues, referred to as apical periodontitis, is of central importance 
in the practice of endodontics.  In fact, the ultimate biological aim of root canal treatment 
itself is to prevent or cure apical periodontitis (24).     
The apical inflammatory response to infection of the root canal system involves the 
induction of several hundreds of genes.  It is a process that must be carefully regulated in 
order to achieve pathogen clearance and at the same time prevent the consequence of 
unregulated tissue damage. Despite advancements in the understanding of the pathogenesis 
of endodontic disease, there is still much to discover about the genetic regulation of this 
process. 
 
1.3 microRNAs in inflammation and the immune response 
The discovery of microRNAs (miRNAs) is one of the most significant scientific 
breakthroughs in recent years and has dramatically changed the previous view of a linear 
relationship between gene and protein expression (25).  The first miRNAs were characterized 
in 1993; however, they were not recognized as a distinct class of regulators until 2001 when 
the term “microRNA” was introduced (26, 27).  miRNAs are short, non-coding, single 
stranded RNA molecules (18-25 nucleotides long) that mediate RNA-interference through 
post-transcriptional modulation of gene expression.  miRNAs silence genes by binding to 
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complementary sequences of their respective target messenger RNAs (mRNAs) and either 
inhibiting their translation into proteins or initiating cleavage of the mRNA leading to its 
degradation (28).  Each miRNA can target many genes and it is thought that each gene is 
regulated by multiple miRNAs.   
miRNAs play a fundamental role in mediating biological events and are involved in 
virtually all physiologic processes such as proliferation, differentiation, apoptosis, cell fate 
determination, signal transduction and organ development (25).  They have also been 
implicated in a multitude of pathologic states such as cancer, developmental abnormalities, 
cardiovascular diseases, neurodegenerative disorders and inflammatory diseases (29-33).  
They are emerging as novel biomarkers of disease, prognostic indicators, and targets for drug 
therapy.  The high sequence conservation of across species and tissue specificity are just 
some of the properties that make miRNAs ideal biomarkers (34).  Stable miRNAs have 
recently been identified in many body fluids including saliva and plasma, which allows for a 
non-invasive means to easily measure miRNA profiles (35, 36).  Functional miRNAs have 
also been discovered in exosomes, which presents a novel strategy to deliver RNA 
therapeutic agents (37).  miRNA-based technology is currently being implemented in a wide 
range of applications such as cancer diagnosis and prognosis, predicting risk of transplant 
rejection, determining the quality of stored blood, and prenatal diagnostics (38).  
miRNAs have been demonstrated to play an important role in the regulation of 
inflammation and the immune response and their role in dentistry is just beginning to be 
explored.     Altered miRNA expression levels have been demonstrated in periodontal disease 
by comparing healthy and inflamed gingival tissues (39-41).  The first miRNA study in the 
field of endodontics found significant differential expression of several miRNAs between 
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healthy and diseased human dental pulps (42).  miRNAs from the miR-181 family were 
among those identified, whose targets include IL-6 – one of the most important mediators of 
the acute phase of the inflammatory response and a key player in the stimulation of 
osteoclastic activity.  Although some insight has been gained on the role of miRNAs in 
endodontic pulpal disease, its role in endodontic periapical pathogenesis has not been 
explored.  The purpose of this study is to determine the differential expression of miRNAs in 
diseased periapical tissues by comparing the miRNA profiles of diseased periapical tissues 
and healthy control tissues. 
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CHAPTER 2 
MicroRNAs: New Insights Into the Pathogenesis of Endodontic Periapical Disease 
Introduction: 
The discovery of microRNAs (miRNAs) is one of the major scientific breakthroughs 
in recent years and has dramatically changed the view of a linear relationship between gene 
and protein expression (25).  miRNAs are short, non-coding, single stranded RNA molecules 
(18-25 nucleotides long) that mediate RNA-interference through post-transcriptional 
modulation of gene expression.  miRNAs silence genes by binding to complementary 
sequences of their respective target messenger RNAs (mRNAs) either inhibiting their 
translation into proteins or initiating cleavage of the mRNA leading to its degradation (28).  
Each miRNA can target many genes and it is thought that each gene is regulated by multiple 
miRNAs.   
miRNAs play a fundamental role in mediating biological events and are involved in 
virtually all physiologic processes (25).  They have also been implicated in a multitude of 
pathologic states such as cancer, developmental abnormalities, cardiovascular diseases, 
neurodegenerative disorders and inflammatory diseases (29-33).  miRNAs are emerging as 
novel biomarkers of disease, prognostic indicators, and targets for drug therapy.  Their high 
sequence conservation across species and tissue specificity are just some of their properties 
that make them ideal biomarkers (34).  Stable miRNAs have recently been identified in many 
body fluids including saliva and plasma, which allows for a non-invasive means to easily 
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measure miRNA profiles (35, 36).  Functional miRNAs have also been discovered in 
exosomes, which presents a novel strategy to deliver RNA therapeutic agents (37).  miRNA-
based technology is currently being implemented in a wide range of applications such as 
cancer diagnosis and prognosis, predicting risk of transplant rejection, determining the 
quality of stored blood, and prenatal diagnostics (38). 
miRNAs have been demonstrated to play an important role in the regulation of 
inflammation and the immune response and their role in dentistry is just beginning to be 
explored.     Altered miRNA expression levels have been demonstrated in periodontal disease 
by comparing healthy and inflamed gingival tissues (39-41). The first miRNA study in the 
field of endodontics found significant differential expression of several miRNAs between 
healthy and diseased human dental pulps (42).  miRNAs from the miR-181 family were 
among those identified, whose targets include IL-6 – one of the most important mediators of 
the acute phase of the inflammatory response and a key player in the stimulation of 
osteoclastic activity.  Although some insight has been gained on the role of miRNAs in 
endodontic pulpal disease, its role in endodontic periapical pathogenesis has not been 
explored.  The purpose of this study is to determine the differential expression of miRNAs in 
diseased periapical tissues by comparing the miRNA profiles of diseased periapical tissues 
and healthy control tissues. 
 
Materials and Methods: 
Study participants and sample collection: This study was approved by the Institutional 
Review Board, at the University of North Carolina at Chapel Hill. The inclusion criteria 
were patients of age ≥12 years old and American Society of Anesthesiologists class I or II. 
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Patients who were immune compromised or currently taking antibiotics or other 
medications known to influence the immune response were excluded from the study.  
Written informed consent was obtained from all study participants. 
Diseased periapical tissues were collected from teeth undergoing surgical 
endodontic treatment (apicoectomy).  These teeth had previous non-surgical endodontic 
treatment and were associated with a non-healing periapical lesion. During the apicoectomy 
procedure, granulation tissue from the periapical lesion was curetted from the bony cavity 
prior to root end resection.  Two different types of tissues were used as controls: normal 
periodontal ligament and pulp tissues.  These were collected from extracted non-carious 
third molars or premolars. Healthy periodontal ligament was collected immediately 
following extraction using a scaling instrument to separate the tissues from the surface of 
the root.  Healthy pulp tissue was extirpated using sterilized barbed broaches immediately 
after extraction.  Tissues samples were placed in a sterile eppendorf tube with 0.5ml 
RNAsafer Stabilizer Reagent (VWR, Bridgeport, NJ) and stored at -80
o
 C until processing.  
13 samples (eight diseased periapical tissues and five healthy pulps) were used for the 
microarray experiment and 19 samples (eight diseased periapical tissues, eight periodontal 
ligaments and three healthy pulps) were used for qRT- PCR.   
 
RNA isolation and miRNA microarray: Samples were thawed on ice and centrifuged at 4
o
C 
for 2 minutes at 12,000 rpm to remove the stabilizer reagent. Total RNA was extracted 
using the miRNeasy Mini kit (Qiagen, Valencia, CA) according to manufacturer’s 
instructions. The RNA was quantitated using the NanoDrop (Thermo Scientific, 
Wilmington, DE) and RNA integrity assessed using the 2100 Bioanalyzer (Agilent, Foster 
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City, CA). The miRNA expression profiles were interrogated using Human miRNA 
Microarrays (V3) and the miRNA Complete Labeling and Hyb Kit (both from Agilent 
Technologies, Santa Clara, CA). The microarrays consist of glass slides containing 8 
identical 15K oligonucleotide microarrays incorporating probes for 866 human miRNAs 
represented from the Sanger miRBase 12.0. The procedure was performed as described 
previously (42).  Slides were scanned using the Agilent Microarray Scanner and the Agilent 
Feature Extraction Software version 10.5.1.1 (both from Agilent, Foster City, CA).  
 
Bioinformatics miRNA analysis and target selection:  Potential mRNA target genes for 
differentially expressed miRNAs in diseased periapical tissues were identified using 
miRWalk (http://www.rna.uni-heidelberg.de/apps/zmf/mirwalk/index_html). miRWalk is a 
comprehensive database that provides information on human and murine miRNAs on their 
predicted and validated targets associated with genes, pathways, diseases, organs, cell lines 
and transcription factors.  It is based on a comparison of computed mRNA 3’ UTRs 
miRNA binding sites with 8 miRNA-target prediction programs.  Candidate mRNAs were 
selected if they were identified as validated miRNA targets in at least 5 out of 8 databases 
and were linked to immunity, inflammation and pain by GO Biological Process 
(www.geneontology.org).  Results from miRWalk and PUBMED search were integrated to 
reach our final results. 
 
Quantitative RT-PCR: 9 miRNAs that demonstrated significant differential expression in the 
microarray analysis and were known to be linked to inflammation and the immune response 
were selected for further validation using qRT-PCR.  miScript primers and miScript II RT 
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Kit were purchased from Qiagen (Germantown, MD, USA). 450 ng total RNA was reverse 
transcribed using cDNA synthesis kit according to manufacturer’s instructions. The PCR 
reactions were run using miRNA specific primers and the miScript universal primer (Qiagen, 
Catalogue #: MS00006692, MS00006699, MS00008841, MS00031500, MS00007588, 
MS00009744, MS00031878, MS00010906, MS00003570, MS00007518).  20 μl reaction 
mixes were prepared using 2X EvaGreen Master Mix (Biotium, Hayward, CA, USA), 2 μl of 
1:10 diluted cDNA, and 10 pmoles of each forward and reverse primer. The real-time PCR 
was carried out in the StepOne 7500 thermocycler (Applied Biosystems, Carlsbad CA, 
USA). SNORD 44 served as an internal control and all reactions were run in triplicates. 
 
Statistical analysis: For microarray data analysis, any expression value that was lower than 
the reported error for that particular gene (which includes negative expression values) was set 
to be equal to the estimated error rate. Quantile normalization was applied to the expression 
data. To identify genes that were differentially expressed in each group, we applied a 
permutation test to test the null hypothesis that the mean expression of each gene was the 
same in both groups. An exact hypothesis test was used since the sample size was small. We 
used the resulting p-values to estimate the false discovery rate q-value when the differential 
expression of each miRNA is called "significant". For each resulting p-value, we computed 
the q-value, which is defined to be the false discovery rate when all tests with a p-value less 
than or equal to the given p-value are called “significant.” 
For qRT-PCR analysis, the relative expression of miRNA as compared SNORD44 
was computed using the 2
(-ΔΔCt) 
method (43).  Significance was determined by applying 
Welch’s t-test to the relative fold changes of periapical tissues and control tissues.  
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Differences were considered significant when the probability value was less than 5% 
(P<0.05). 
 
Results:  
No significant differences were noted in gender distribution between experimental and 
control groups.  However, there was a significant difference in age between subjects from 
which periapical tissue were collected and subjects from which healthy PDL and pulp were 
collected (P < 0.05).  The mean age of the periapical group was 53 yrs. (±15), while that of 
the PDL controls was 28 yrs. (±16), and that of the pulp group was 18 yrs. (±3).  Two 
subjects from which periapical lesion tissue was collected for qRT-PCR analysis experienced 
pain symptoms associated with the tooth prior to sample collection, while the remaining were 
asymptomatic.   
 
Microarray results 
Of the 381 human miRNAs identified in periapical tissues, 24 miRNAs were significantly 
down-regulated (P < .003, q < .08) in periapical tissues compared to healthy pulp control 
tissues.  Of these 24 down-regulated miRNAs, 15 showed a 2-5 fold change and six had more 
than a five-fold change (Fig. 1).  Of the 24 down-regulated miRNAs identified, nine miRNAs 
that are linked to inflammation and immunity were selected for further analysis with qRT-
PCR.  The fold change in expression of these nine miRNAs ranged from 2.4 to 10.8. 
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qRT-PCR results 
The comparison between healthy periodontal ligament samples and diseased periapical tissue 
samples  showed a significant down-regulation of seven out of nine miRNAs tested  (P < .05) 
(Fig. 2).  The fold change for this comparison varied from 1.2-fold to 21.2-fold.  miR-95 was 
down-regulated 1.2 fold while the remaining six miRNAs were down-regulated more than 4-
fold.   These same seven miRNAs were also significantly down-regulated when comparing 
healthy pulp tissues to periapical lesion tissues (P ≤ .001) (Fig. 3).  The fold regulation for 
this comparison varied from 16-fold to 45-fold.  These results were similar to those obtained 
with microarray as both showed significant down-regulation of the seven miRNAs, however 
the magnitude of the fold change was greater with qRT-PCR (16 to 45 fold change) 
compared to microarray (2.4 to 10.8 fold change).  The remaining two miRNAs, miR-455-5p 
and miR-181d, were not detected in the samples using qRT-PCR. 
 
Bioinformatics data 
The potential targets of the differentially expressed miRNAs identified include key cytokines 
involved in inflammation (IL-6, IL-10), chemokines (CCL8), pathogen recognition receptors 
(TLR-4), growth factors (TGF-β1, VEGF-α) and proteins involved in macrophage 
differentiation and the immune response to LPS (MMP-9) (Table 1). 
 
Discussion: 
In this study, multiple miRNAs from the miR-181 family (miR-181a*, miR-181b and 
miR-181c) were demonstrated to be significantly down-regulated in diseased periapical 
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tissues compared to healthy control tissues.  Down-regulation of miRNAs, which are 
negative regulators themselves, results in an increase in their respective target messenger 
RNAs (mRNA).  The targets of miR-181a* include toll-like receptor-4 (TLR-4), which plays 
a key role in pathogen recognition and  activation of the innate immune response, and IL-6, 
which stimulates neutrophil production and supports B-cell maturation.  miR-181b also 
targets IL-6 as well as CCL-8, MMP-9 and TGF-B1, which are involved in a wide range of 
inflammatory pathways.  For example, CCL-8 is chemotactic for and activates several 
immune cells including monocytes, T cells and NK cells.  MMP-9 is closely associated with 
macrophage differentiation and TGF-β1 increases collagen biosynthesis and fibroblast 
proliferation.  The targets of miR-181c include SOCS1, which is involved in the LPS 
response, and IL-2, which plays an essential role in the immune response to antigenic stimuli 
and is important for the proliferation of T and B lymphocytes.  The miR-181 family is also 
notable for altering T-cell receptor signaling and increasing IFN-γ/IL-17 production by 
Th1/17 cells. 
Increasing evidence supports the role of the miR-181 family in inflammatory 
pathologies. Circulating levels of miR-181a, miR-181a-2* and miR181c in whole blood were 
significantly lower in patients diagnosed with complex regional pain syndrome, a disorder in 
which neurogenic inflammation plays a key role (44). Blood plasma levels of miR-181b was 
found to be lower in patients with sepsis (a whole body inflammatory condition due to 
infection) and in animal models of sepsis (45). Data from our previous study show that 
members of the miR-181 family are down-regulated in inflamed human pulps as compared to 
normal pulps (p≤0.001) (42). Conversely, miR-181c is upregulated in inflamed gingival 
tissues (40). These differences in expression of miR-181c in distinct inflammatory 
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pathologies could possibly be due to differences in the type of infection or the host tissue or 
the sampling point after initiation of inflammation. 
 In addition to the miR-181 family, miR-24-1*, miR-95, miR-149 and miR-455-3p 
were significantly down-regulated in diseased periapical tissues.  These miRNAs also have a 
variety of targets that are implicated in the immune and inflammatory response.  For 
example, miR-149 targets VEGF-α, which acts on endothelial cells to mediate increased 
vascular permeability and promote cell migration to the site of inflammation.  miR-455-3p 
targets TLR-4 as well as IL-10, a cytokine produced primarily from monocytes that serve to 
enhance B cell survival, proliferation and antibody production. 
 A limited number of studies have examined miRNA expression in inflammation 
related to endodontic infection.  Our previous study examined the differential expression of 
miRNAs in inflamed and healthy pulps using microarray techniques (42).  When comparing 
our microarray data to that of our previous study, we see that there is significant differential 
expression of 13 of the same miRNAs in both periapical and pulp tissues.  These include: 
miR-29a*, miR-30b*, miR-181a-2*, miR-181d, miR-455-5p, miR199-5p and miR-664.  All 
seven of the significantly down-regulated miRNAs identified in diseased periapical tissues 
were also shown to be down-regulated in inflamed pulp tissue compared to healthy pulp 
tissue.  The six of which showed significant down-regulation in both tissues include: miR-24-
1*, miR-95, miR-181a*, miR-181b, miR-181c and miR-455-3p. The extent of this cross-over 
suggests some common miRNA regulatory network in pulpal and periapical disease 
pathogenesis.  This could be due to similar inflammatory processes occurring in both tissues.  
However, the tissue specificity of miRNAs is apparent in the difference between the types of 
miRNAs identified in pulp and periapical tissues using microarray.  Although some overlap 
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exists, it is possible that the other miRNAs identified in this study could be unique to the 
periapical disease process. 
 The limitations of this study include the small sample size and age matched controls 
were not used.  Both PDL and pulp were used as control tissues.  In the absence of periapical 
disease the tissues present in the periapex consist of PDL, pulp and bone tissue.  Bone tissue 
was not included as a control since its removal is not recommended in apicoectomy 
procedures as this could delay healing.  Bone tissue is also relatively acellular and its cellular 
components are difficult to isolate from the hard tissue.  After the microarray experiments, an 
additional cohort of tissue samples were collected for qRT-PCR analysis.  Despite using new 
tissue samples for the qRT-PCR, the results confirmed the down-regulation of the same 
miRNAs identified using microarray.  Also, the same miRNAs were consistently down-
regulated in diseased periapical tissues when comparing to both pulp and PDL control 
tissues.  This correlation strengthens the findings and supports the inclusion of the selected 
control tissues.  The magnitude of down-regulation of the seven miRNAs was greater when 
comparing diseased periapical tissues to pulp controls than when comparing to PDL controls.  
This may be due to higher baseline expression levels of the miRNAs in the pulp since it is 
more cellular in nature than PDL. 
A significant difference in mean age between groups from which tissue samples were 
collected was observed.  Participants in the PDL and pulp control groups consisted primarily 
of younger individuals undergoing extraction of third molars or premolars for orthodontic 
purposes.  Participants in the periapical group were older as these teeth had previous 
endodontic treatment and were planned for apicoectomy surgery.     
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 Future studies that include a larger number of subjects are necessary to identify any 
miRNAs that might correlate with pain symptoms.  Studies that implement in situ 
hybridization techniques could be used to determine the cellular sources of the identified 
miRNAs.  Confirmation of the altered target gene expression could then be investigated with 
miRNA overexpression or knockdown studies. 
 This study explores the role of miRNAs in endodontic disease and provides new 
insight into the genetic regulation of endodontic periapical pathogenesis.  Seven specific 
miRNAs that target key mediators in the inflammatory and immune response were 
determined to be significantly down-regulated in diseased periapical tissues. This study 
offers potential candidates for further investigation of miRNAs in endodontic disease.  These 
findings could facilitate the development of potential biomarkers and possible therapeutic 
targets for the treatment of endodontic disease. 
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Figures & Tables: 
 
 
 
Figure 1. Differential expression of miRNAs in healthy pulp (n = 5) and diseased periapical 
tissues (n = 8) evaluated by microarray.   Twenty-four miRNAs were significantly down-
regulated in diseased periapical tissues (P < .003, q < .08).  Data was analyzed using an exact 
hypothesis test and expressed as log values. 
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Figure 2. Relative fold changes of seven miRNAs in diseased periapical and healthy 
periodontal ligament tissues analyzed by qRT-PCR.  Data was normalized to expression of 
endogenous control, SNORD44.  Relative expression computed using the 2
(-ΔΔCt)
 method. *   
P ≤ .001, ** P ≤ 0.05 
 
 
Figure 3.  Relative fold changes of seven miRNAs in diseased periapical and healthy pulp 
tissues analyzed by qRT-PCR.  Data was normalized to expression of endogenous control, 
SNORD44.  Relative expression computed using the 2
(-ΔΔCt)
 method.  *   P ≤ .001   
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Table 1. Potential miRNA target genes were identified using PUBMED and miRWalk 
(http://www.rna.uni-heidelberg.de/apps/zmf/mirwalk/index_html). 
 
 
 
 
 
 
 
 
 
 
 
 
 
miRNA Target gene Gene product function GO Term (Accession, Ontology)
miR-181a TLR-4
Toll-l ike receptor-4 (TLR) plays a fundamental role in pathogen 
recognition and activation of innate immunity
GO:0035662, Molecular Function
IL-6 Acute and chronic inflammation and the maturation of B cells GO:0019981, Molecular Function
miR-181b IL-6
Negative regulation of cytokine secretion; negative regulation 
of collagen biosynthetic process; positive regulation of acute 
inflammatory response; response to cold, heat and 
mechanical stimuli 
GO:0005138, Molecular Function
CCL8
Immune response, inflammatory response, chemokine 
activity, phospholipase activator
MMP9
Cell response to IL-1, LPS; macrophage differentiation; 
response to heat and mechanical stimuli; positive regulation 
of apoptosis and angiogenesis
GO:0004229, Molecular Function
TGFB1
Adaptive immune response; positive regulation of collagen 
biosynthesis, chemotaxis, fibroblasts migration, and 
ondontogenesis
GO:0034713, Molecular Function
miR-181c SOCS1
Cytokine mediated signaling pathway; negative regulator of 
JAK-STAT pathway; LPS response  
IL-2
Cytokine produced by T-cells in response to antigen or 
mitogen stimulation
GO:0005134, Molecular Function
miR-24
MAPK14
MAP kinase activated by various environmental stresses and 
proinflammatory cytokines, act as an integration point for multiple 
biochemical signals GO:0051403, Biological Process
miR-95 EIF2C2
Eukaryotic translation initiation factor interacted with dicer1 in short-
interfering-RNA-mediated gene silencing
miR-149
VEGFA
Increased vascular permeability, angiogenesis, vasculogenesis and 
endothelial cell  growth, promoting cell migration, and inhibiting 
apoptosis GO:0035924, Biological Process
miR-455
IL-10
Pleiotropic effects in immunoregulation and inflammation, B 
cell survival, proliferation, and antibody production, block NF-
kappa B activity GO:0019969, Molecular Function
TLR-4
Toll-l ike receptor-4 (TLR) plays a fundamental role in pathogen 
recognition and activation of innate immunity
GO:0035662, Molecular Function
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CHAPTER 3: CONCLUSION 
In this study, 24 miRNAs were found to be significantly down-regulated in periapical 
tissues compared to healthy control tissues using microarray techniques.  Of these 24 
miRNAs, 9 which were linked to immunity and inflammation were then subjected to further 
validation using qRT-PCR.  Additional tissue samples were collected for qRT-PCR and 
results showed significant down-regulation of 7 of the 9 miRNAs tested when comparing 
diseased periapical tissue to both healthy pulp and periodontal ligament tissues.   
Multiple miRNAs from the miR-181 family (miR-181a*, miR-181b and miR-181c) 
were among those identified to be significantly down-regulated in diseased periapical tissues.  
Down-regulation of miRNAs, which are negative regulators themselves, results in an 
increase in their respective target messenger RNAs (mRNA).  The targets of miR-181a* 
include toll-like receptor-4 (TLR-4), which plays a key role in pathogen recognition and  
activation of the innate immune response, and IL-6, which stimulates neutrophil production 
and supports B-cell maturation.  miR-181b also targets IL-6 as well as CCL-8, MMP-9 and 
TGF-B1, which are involved in a wide range of inflammatory pathways.  For example, CCL-
8 is chemotactic for and activates several immune cells including monocytes, T cells and NK 
cells.  MMP-9 is closely associated with macrophage differentiation and TGF-β1 increases 
collagen biosynthesis and fibroblast proliferation.  Studies using animal models have also 
implicated miR-181b in the regulation of NF-kB-mediated endothelial cell activation and 
vascular inflammation and suggests that rescue of miR-181b expression could be 
 23 
 
implemented in anti-inflammatory therapy (45).  The targets of miR-181c include SOCS1, 
which is involved in the LPS response, and IL-2, which plays an essential role in the immune 
response to antigenic stimuli and is important for the proliferation of T and B lymphocytes.   
Many miRNAs from the miR-181 family have been implicated in various 
inflammatory pathologies. For example, circulating levels of miR-181a, miR-181a-2* and 
miR181c are significantly lower in patients diagnosed with complex regional pain syndrome, 
a disorder in which neurogenic inflammation plays a key role (44). In addition, circulating 
levels of miR-181b are lower in patients with sepsis (a whole body inflammatory condition 
due to infection) and in animal models of sepsis (45). Data from our previous study show that 
members of the miR-181 family are down-regulated in inflamed human pulps as compared to 
normal pulps (p≤0.001) (42). Conversely, miR-181c is upregulated in inflamed gingival 
tissues (40). These differences in expression of miR-181c in distinct inflammatory 
pathologies could possibly be due to differences in the type of infection or the host tissue or 
the sampling point after initiation of inflammation. 
 In addition to the miR-181 family, miR-24-1*, miR-95, miR-149 and miR-455-3p 
were significantly down-regulated in diseased periapical tissues.  These miRNAs also have a 
variety of targets that are implicated in the immune and inflammatory response.  For 
example, miR-149 targets VEGF-α, which acts on endothelial cells to mediate increased 
vascular permeability and promote cell migration to the site of inflammation.  miR-455-3p 
targets TLR-4 as well as IL-10, a cytokine produced primarily from monocytes that serve to 
enhance B cell survival, proliferation and antibody production. 
 A limited number of studies have examined miRNA expression in inflammation 
related to endodontic infection.  Our previous study examined the differential expression of 
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miRNAs in inflamed and healthy pulps using microarray techniques (42).  When comparing 
our microarray data to that of our previous study, we see that there is significant differential 
expression of 13 of the same miRNAs in both periapical and pulp tissues.  These include: 
miR-29a*, miR-30b*, miR-181a-2*, miR-181d, miR-455-5p, miR199-5p and miR-664.  Of 
the seven significantly down-regulated miRNAs identified in diseased periapical tissues, six 
miRNAs have also been shown to be down-regulated in inflamed pulp tissue compared to 
healthy pulp tissue.  These include miR-24-1*, miR-95, miR-181a*, miR-181b, miR-181c 
and miR-455-3p. The extent of this cross-over suggests a common miRNA regulatory 
network in pulpal and periapical disease pathogenesis. 
Future studies that include a larger number of subjects are necessary to identify any 
miRNAs that might correlate with pain symptoms.   In this study, only two subjects 
presented with pain symptoms prior to periapical tissue collection.  A larger scale study 
could include more symptomatic patients which would allow for statistical analysis to 
determine if any specific miRNAs show differential expression between patients 
experiencing pain and asymptomatic patients.  Future studies could also investigate the 
cellular sources of the identified differentially expressed miRNAs.    Formalin fixed 
periapical lesion tissues collected from apicoectomy procedures could be used with in situ 
hybridization techniques to determine which cell types each of the identified miRNAs is 
expressed in.  In the present study, samples were determined to be periapical granulomas 
rather than cysts based on only clinical impression.  However, in situ hybridization would 
allow for confirmation of the type of lesion while also providing a qualitative determination 
of differential expression of miRNAs.  Identifying the cellular sources of the differentially 
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expressed miRNAs could also shed light on whether the observed changes in their expression 
levels are solely due to a change in the cell profile of the lesion or not. 
In addition, the down-stream effects of altered miRNA expression could be explored.  
Gene-specific experimental validation of miRNA targets can be done to identify individual 
miRNA:mRNA interactions.  Downstream effects of differential miRNA expression can be 
observed at the protein level by western blot and at the mRNA level by qRT-PCR.  
Confirmation of the altered target gene expression could then be investigated with miRNA 
overexpression or knockdown studies.  Over-expression can be achieved using transient 
transfection of a synthetic miRNA precursor or by stable introduction of a miRNA 
expression construct such as a lentiviral vector (46).  miRNAs can be inhibited by expressing 
modified antisense oligonucleotides that bind to mature miNRAs thus blocking their activity.  
Animal studies could also be used to sample lesions throughout the healing process in order 
to determine whether there are changes in the miRNA profiles at different stages of healing. 
 This study is the first to explore the role of miRNAs in periapical disease, providing 
new insight into the genetic regulation of endodontic disease.  Seven specific miRNAs that 
target key mediators in the inflammatory and immune response were determined to be 
significantly down-regulated in diseased periapical tissues. This study begins to elucidate the 
complex miRNA regulatory network in endodontic disease and offers potential candidates 
for further investigation.  The identified miRNAs have potential to serve as possible 
biomarkers or therapeutic targets for the treatment of endodontic disease. These findings 
could facilitate the development of improved methods of diagnosis and management of 
endodontic disease. 
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